Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended March 31, 2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ___________ to _______________

Commission File Number: 333-251016

CANNAPHARMARX, INC.

(Exact name of small business issuer as specified in its charter)

Delaware		27-4635140
(State of other jurisdiction of incorporation)		(IRS Employer ID No.)

Suite 3600

888 – 3^rd Street SW

Calgary, Alberta, Canada T2P 5C5

(Address of principal executive offices)

949-652-6838

(Issuer’s Telephone Number)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CPMD	OTC Pink Sheets

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. ☐ Yes ☒ No

The number of shares of the registrant’s only class of common stock issued and outstanding as of September 22, 2023, was 300,862,715 shares.

TABLE OF CONTENTS

		Page No.

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	4

	Unaudited Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022	4

	Unaudited Condensed Consolidated Statement of Operations for the Three Months Ended March 31, 2023 and 2022	5

	Unaudited Condensed Consolidated Statement of Cash Flows for the Three Months Ended March 31, 2023 and 2022	6

	Unaudited Condensed Consolidated Statements of Stockholders Equity (Deficit)	7

	Notes to Unaudited Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation	22

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

Item 4.	Controls and Procedures	27

	PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	29

Item 1A.	Risk Factors	30

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30

Item 3.	Defaults Upon Senior Securities	30

Item 4.	Mine Safety Disclosures	30

Item 5.	Other Information	30

Item 6.	Exhibits	30

	Signatures	31

Forward Looking Statements

This Report includes statements that are, or may be deemed to be, “forward-looking statements,” as defined in the Private Securities Reform Act of 1995. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “projects,” “expects,” “intends,” “may,” “will,” “seeks” or “should” or, in each case, their negative or other variations or comparable terminology, or in relation to discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include matters that are not historical facts. They appear in a number of places throughout this Quarterly Report and include statements regarding Issuer’s current intentions, beliefs or expectations concerning, among other things, the Issuer’s future plans for the Project, results of operations, financial condition, prospects, growth, strategies and the markets in which the Issuer intends to operate.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not an assurance of future performance. The Issuer’s actual results of operations and financial condition may differ materially from those suggested by the forward-looking statements contained in this document. In addition, even if the Issuer’s future results of operations and financial condition are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. The information in this Quarterly Report identifies important factors that could cause such differences (including, but not limited to, a change in overall economic conditions in the United States, a change in the Issuer’s financial condition, changes in tax law or the interpretation thereof, interest rate fluctuations and other market conditions, and the effect of new legislation or government directives).

Forward-looking statements include, but are not limited to, information concerning possible or assumed future results of the Issuer’s operations set forth under the section entitled “Business of the Issuer”. Such statements, estimates and projections reflect various assumptions by the Issuer concerning anticipated results and are subject to significant business, financing, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Issuer and are based upon assumptions with respect to future business decisions that are subject to change. Accordingly, there can be no assurance that such statements, estimates and projections will be realized or that actual results will not vary considerably from those anticipated, expected or projected. The Issuer, its accountants, its legal advisers and its agents or affiliates do not make any representations as to the accuracy or completeness of such statements, estimates and projections, or that any forecasts will be achieved.

The Issuer is not obliged to, and does not intend to, update or revise any forward-looking statements made in this Quarterly Report whether as a result of new information, future events or otherwise. All subsequent written forward-looking statements attributable to the Issuer, or persons acting on behalf of the Issuer, are expressly qualified in their entirety by the cautionary statements contained throughout this Quarterly Report. As a result of these risks, prospective investors of the Convertible Bonds should not place undue reliance on these forward-looking statements. Neither the forward-looking statements nor the underlying assumptions have been verified or audited by any third party.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CANNAPHARMARX, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)


	March 31,			December 31,
	2023			2022
ASSETS
Current assets
Cash	$	–		$	2,317
HST Receivable		29,612			23,251
Prepaid expense		74,463			68,539
Other assets		–			5,906
Total current assets		104,075			100,014
Property, plant and equipment, net		102,848			107,780
Right of use building, net		5,064,265			5,127,622
Investments		–			78,760
Total Assets	$	5,271,189		$	5,414,176


LIABILITIES & STOCKHOLDERS' DEFICIT

Current liabilities
Accounts payable and accrued expenses	$	7,178,180		$	6,882,947
Cash overdraft		34,050			–
Accrued interest		183,423			151,925
Accrued legal settlement		190,000			190,000
Notes payable		7,721,894			7,715,858
Convertible notes -net of discount		1,344,252			1,141,060
Derivative liability		772,611			1,008,868
Loan payable - related parties		414,056			74,497
Total current liabilities		17,838,466			17,165,154
Liability for right of use building long-term		5,643,148			5,593,477
Total Liabilities		23,481,614			22,758,632

Commitments and contingencies		–			–

Stockholders' Deficit
Preferred stock, Series A, $1.00 par value, 100,000 shares authorized, 84,416 and 84,416 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		84,416			84,416
Preferred Stock Series B, $1.00 par value, 3,000,000 shares authorized 2,455,000 and 2,475,000 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		2,455,000			2,475,000
Common stock, $0.0001 par value; 5,000,000,000 shares authorized, 294,764,614 and 274,124,622 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		29,476			27,412
Treasury stock, 133,200 and 133,200 shares as of March 31, 2023 and December 31, 2022, respectively		(13	)		(13	)
Additional paid in capital		75,093,838			74,523,642
Accumulated deficit		(96,107,912	)		(94,695,339	)
Accumulated other comprehensive income (loss)		234,770			240,427
Total Stockholders' (Deficit)		(18,210,425	)		(17,344,455	)
Total Liabilities and Stockholders' (Deficit)	$	5,271,189		$	5,414,176

The accompanying notes are an integral part of these consolidated financial statements.

CANNAPHARMARX, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months			Three Months
	Ended			Ended
	March 31,			March 31,
	2023			2022
Revenue	$	–		$	–

Operating Expenses:
General and administrative		249,699			139,435
Amortization and depreciation		73,399			74,064
Stock based compensation		45,245			45,245
Rent		2,593			4,739
Professional fees		26,201			177,404
Payroll and consulting fees		323,140			274,671
Total operating expenses		720,277			715,558
Loss from operations		(720,277	)		(715,558	)

Other income (expense)
Interest (expense)		(459,345	)		(451,148	)
Gain or (loss) on the extinguishment of debt		(390,447	)		(320,243	)
Loss on investments		(78,760	)		–
Change in the fair value of derivative liability		236,256			(585,033	)
Other (expense) net		(692,296	)		(1,356,424	)
Loss before provision for income taxes		(1,412,573	)		(2,071,982	)
Provision (credit) for income tax		–			–
Net (loss)	$	(1,412,573	)	$	(2,071,982	)

Basic and diluted (loss) per common share	$	(0.00	)	$	(0.01	)

Weighted average number of shares outstanding		292,889,614			149,215,596

Comprehensive loss:
Net loss	$	(1,412,573	)	$	(2,071,982	)
Foreign currency translation adjustment		(5,656	)		(120,750	)
Comprehensive (loss)	$	(1,418,229	)	$	(2,192,732	)

Supplemental disclosure of non-cash investing and financing activities:
Common stock issued as financing expense on convertible notes	$	–		$	17,000
Common stock issued to convert convertible notes and accrued interest into equity	$	507,015		$	501,905

The accompanying notes are an integral part of these consolidated financial statements.

CANNAPHARMARX, INC.

STATEMENTS OF CONSOLIDATED CASH FLOWS

(Unaudited)


	Three Months			Three Months
	Ended			Ended
	March 31, 2023			March 31, 2022

Cash Flows From Operating Activities:
Net (loss)		(1,412,573	)		(2,071,982	)
Adjustments to reconcile net income to net cash provided by (used in) operating activities
Stock-based compensation expense		45,245			45,245
Loss on investments		78,760			–
Beneficial conversion feature of convertible notes		–			227,386
Amortization of debt discount		162,392			100,971
Loss on the extinguishment of debt		390,447			320,243
Change in the fair value of derivatives		(236,256	)		585,033
Depreciation		5,826			942
Changes in operating assets and liabilities
HST Receivable		(6,342	)		(4,098	)
Right of use asset		–			(5,727,811	)
Prepaids		(5,924	)		–
Other assets		5,906			–
Lease liabilities for right of use asset		–			5,850,761
Accrued interest		31,498			16,633
Accrued expense related party		–			47,387
Accounts payable and accrued expense		329,283			234,106
Net cash (used in) operating activities		(611,739	)		(375,184	)

Cash Flows From Investing Activities:
Purchase of fixed assets		(893	)		(16,578	)
Net cash (used in) investing activities		(893	)		(16,578	)

Cash Flows From Financing Activities:
Proceeds from convertible notes		153,750			–
Proceeds from notes payable		339,559			476,250
Proceeds from the sale of common stock in private placements		–			40,015
Net cash provided by financing activities		493,309			516,265

Effect of exchange rates on cash and cash equivalents		117,005			(72,594	)
Net Increase (Decrease) In Cash		(2,317	)		51,909
Cash At The Beginning Of The Period		2,317			27,767
Cash At The End Of The Period	$	–			79,676

Supplemental disclosure of cash flow information:
Cash paid for interest	$	–		$	–
Cash paid for income taxes	$	–		$	–

Supplemental disclosure of non-cash investing and financing activities:
Common stock issued as a financing expense on convertible notes	$	–		$	17,000
Common stock issued to convert convertible notes and accrued interest into equity	$	–		$	501,905

The accompanying notes are an integral part of these consolidated financial statements.

CANNAPHARMARX, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

Preferred Stock
Series A

Preferred Stock
Series B

Common Stock

Treasury Stock

Paid in

Accumulated

Accumulated other comprehensive

Equity/

Value

Capital

deficit

income (loss)

Deficit

Balance, December 31, 2021

67,191

475,000

125,509,810

12,551

133,200

(13

)

73,055,579

(86,164,319

)

(371,909

)

(12,925,920

)

Net (loss)

–

(2,071,982

)

–

(2,071,982

)

Change in foreign currency translation

–

(120,750

)

(120,750

)

Conversion of Series A Preferred to common stock

(9,011

)

(9,011

)

–

11,263,750

1,126

–

7,885

–

Conversion of convertible notes to common shares

–

28,186,741

2,819

–

499,096

–

501,915

Sale of common stock in private placement

–

2,500,000

250

–

39,765

–

40,015

Issuance of Series B shares for deposit on acquisition

–

Issuance of common stock for services

–

Commitment shares issued with convertible note

–

1,000,000

100

–

16,900

–

17,000

Beneficial conversion feature of convertible notes

–

227,386

–

227,386

Stock based compensation related to warrant issuances

–

45,245

–

45,245

Balance, March 31, 2022

58,180

475,000

168,460,301

16,846

133,200

(13

)

73,891,856

(88,236,301

)

(492,658

)

(14,287,090

)


																									Accumulated
	Preferred Stock Series A				Preferred Stock Series B						Common Stock				Treasury Stock					Paid in		Accumulated			other comprehensive			Equity/
	Shares		Value		Shares			Value			Shares		Value		Shares		Value			Capital		deficit			income (loss)			Deficit
Balance, December 31, 2022		84,416	$	84,416		2,475,000		$	2,475,000			274,124,622	$	27,412		133,200	$	(13	)	$	74,523,642	$	(94,695,339	)	$	240,427		$	(17,344,455	)

Net (loss)		–		–		–			–			–		–		–		–			–		(1,412,573	)		–			(1,412,573	)

Change in foreign currency translation		–		–		–			–			–		–		–		–			–		–			(5,656	)		(5,656	)

Conversion of Series B Preferred to common stock		–		–		(20,000	)		(20,000	)		20,000		2		–		–			19,998		–			–			–

Conversion of convertible notes to common shares		–		–		–			–			20,619,992		2,062		–		–			504,953		–			–			507,015

Stock based compensation related to warrant issuances		–		–		–			–			–		–		–		–			45,245		–			–			45,245

Balance, March 31, 2023		84,416	$	84,416		2,455,000		$	2,455,000			294,764,614	$	29,476		133,200	$	(13	)	$	75,093,838	$	(96,107,912	)	$	234,770		$	(18,210,425	)

The accompanying notes are an integral part of these consolidated financial statements.

CANNAPHARMARX, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022

NOTE 1.

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

We were originally incorporated in the State of Colorado in August 1998 under the name “Network Acquisitions, Inc.” We changed our name to Cavion Technologies, Inc. in February 1999 and subsequently to Concord Ventures, Inc. in October 2006.

On December 21, 2000, we filed for protection under Chapter 11 of the United States Bankruptcy Code. In connection with the filing, on February 16, 2001, we sold our entire business, and all of our assets, for the benefit of our creditors. After the sale, we still had liabilities of $8.4 million and were subsequently dismissed by the Court from the Chapter 11 reorganization, effective March 13, 2001, at which time the last of our remaining directors resigned. On March 13, 2001, we had no business or other source of income, no assets, no employees or directors, outstanding liabilities of approximately $8.4 million and had terminated our duty to file reports under securities law. In February 2008, we were re-listed on the OTC Bulletin Board.

In April 2010, we re-domiciled in Delaware under the name CCVG, Inc. (“CCVG”). Effective December 31, 2010, CCVG completed an Agreement and Plan of Merger and Reorganization (the “Reorganization") which provided for the merger of two of our wholly-owned subsidiaries. As a result of this reorganization, our name was changed to “Golden Dragon Inc.”, which became the surviving publicly quoted parent holding company.

On May 9, 2014, we entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRx, Inc., a Colorado corporation (“Canna Colorado”), and David Cutler, a former President, Chief Executive Officer, Chief Financial Officer and director of our Company. Under the Share Purchase Agreement, Canna Colorado purchased 1,421,120 shares of our common stock from Mr. Cutler and an additional 9,000,000 restricted common shares directly from us.

On May 15, 2014, as amended and effective January 29, 2015, we entered into an Agreement and Plan of Merger (the “Merger”) pursuant to which Canna Colorado became a subsidiary of our Company.

In October 2014, we changed our legal name to “CannaPharmaRx, Inc.”

Pursuant to the Merger all of the shares of our common stock previously owned by Canna Colorado were canceled. As a result of the aforesaid transactions, we became an early-stage pharmaceutical company whose purpose was to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology then under development.

In April 2016, we ceased operations. Our then management resigned their respective positions with our Company with the exception of Mr. Gary Herick, who remained one of our officers and directors until April 23, 2019.

As a result of the completion of the acquisition of AMS on December 31, 2019, the Company no longer fit the definition of a “shell company,” as defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act. It filed the required disclosure on Form 8-K/A with the SEC on February 14, 2019, advising that it was no longer a shell company pursuant to the aforesaid Rule.

On January 6, 2021, the Company executed an Agreement of Purchase and Sale through its wholly-owned subsidiary, Alternative Medical Solutions Inc for the sale of the lands and premises located at Hanover, Ontario, Canada. The facility sold was a 48,750 square foot marijuana grow facility on a 6.7-acre parcel of land located in Hanover, Ontario, Canada. To point of sale, the exterior construction of the building had been completed, however, no interior construction had begun.

The price was $2,000,000 CAD. As a result, and in anticipation of the closing, the Company recorded an impairment of goodwill and fixed assets relating to the property of $7,962,694 at December 31, 2020. This property was security for a $1,000,000 US Note with Koze Investments LLC by way of a first ranking charge. This transaction closed on July 9, 2021 and the note was repaid in full as principal of $1,000,000 plus accrued interest of $124,735 and penalties of $475,265. The note was discharged accordingly.

Effective February 25, 2019, the Company acquired 3,936,500 shares and 2,500,000 Warrants to purchase 2,500,000 shares of Common Stock of GN Ventures, Ltd, Alberta, Canada, f/k/a Great Northern Cannabis, Ltd. (“GN”), in exchange for an aggregate of 7,988,963 shares of its Common Stock, from a former shareholder of GN who the Company’s President and CEO is now. In May 2020, the Company exchanged 5,507,400 of its shares for 3,671,597 shares of GN.

GN owns a 60,000 square foot cannabis cultivation and grow facility located on 38 acres in Stevensville, Ontario, Canada. Because the Company is a minority shareholder of GN and GN is a privately held company, the Company cannot confirm that the information it currently has on GN’s operations is complete or fully reliable. GN estimates annual total production capacity from the Stevensville facility of up to 12,500 kilograms of cannabis. Once completed the Stevensville facility and GN’s subsidiary, 9869247 Canada Limited, received a license to cultivate from the Canadian Ministry of Health on July 5, 2019. As a result, in October 2019, GN commenced cultivation activities and began generating revenues during the first calendar quarter of 2020.

Effective June 11, 2019, the Company entered into a Securities Purchase Agreement with Sunniva, Inc, a British Columbia, Canada corporation (“Sunniva”) wherein the Company agreed to acquire all of the issued and outstanding securities of Sunniva’s wholly-owned subsidiaries Sunniva Medical Inc. (“SMI”) and 1167025 B.C. LTD (“1167025”) for CAD $16.0 million in cash and a note in the principal amount of CAD $4.0 million. These companies were the owners of the Sunniva Canada Campus, which included construction assets for a planned 759,000 square-foot greenhouse located on an approximately 114-acre property in Okanagan Falls, British Columbia.

Description of Current Business

We are involved in the cannabis industry in Canada. Our principal business activities to date have been to evaluate, negotiate, acquire, and develop cannabis cultivation projects in Canada. As of the date of this report we do not own or operate any businesses in the US.

On January 6, 2022 the Company entered into a 20 year operating lease with Formosa Mountain Ltd. The leased facility is located in Cremona, Alberta, Canada. It was built in 2015 and was previously operating as a cannabis production facility. It was decommissioned and the license was cancelled by the previous owner making it ready for sale in 2020.

CannaPharmaRx recommissioned the facility into a new indoor cannabis farm during 2022. It is a 55,000 square foot facility with 11 growing rooms and 10 drying and packing rooms. The Company received an Operating License from Health Canada on December 9, 2022, and a Cannabis License from the Canada Revenue Agency on December 22, 2022.

On February 21, 2023, the Company entered into a Supply Agreement with Y.S.A. Holdings Ltd (“Y.S.A.), an Israeli corporation. The Company will supply 450kg of cannabis biomass in the form of dried flowers and dried trim per annum, over a two year period. No supplies have been delivered to Y.S.A as of the date of this Report.

Production and sales from this facility are anticipated in Q3 of 2023. The expected date of the first harvest, under the new license, is on or about August 08^th, 2023 with the second harvest in September 2023. Both harvests are expected to yield around 100 kilograms (“kg”) of saleable cannabis flower product.

Preliminary discussion with export partners, would set conditional per gram pricing at approximately $3.30 CDN/gr. This pricing matrix would be based on achieving satisfactory test results associated to tetrahydrocannabinol “THC” and cannabidiol “CBD” content of the dried flower. Expected revenues for both harvests, if sold in their entirety, would be forecasted at $660,000 CDN. A third and fourth harvest are planned in Q4 with similarly forecasted revenues. There can be no assurances that our crops will be successfully harvested, or that we can sell the harvest; and if we are able to sell the harvest, that we can do so at the price/s we expect to receive.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States. Certain amounts in prior periods have been reclassified to conform to the current presentation.

All figures are in U.S. dollars unless indicated otherwise.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates relate to purchase price allocation of acquired businesses, impairment of long-lived assets and goodwill, valuation of financial instruments, income taxes, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid temporary cash investments with an original maturity of the year or less to be cash equivalents. On March 31, 2023, and December 31, 2022, the Company had a cash overdraft and cash equivalents of $(34,050) and $2,317, respectively.

Comprehensive Gain or Loss

ASC 220 “Comprehensive Income,” establishes standards for the reporting and display of comprehensive income and its components in the financial statements. As of March 31, 2023, and December 31, 2022, the Company determined that it had items that represented components of comprehensive income and, therefore, has included a statement of comprehensive income in the financial statements.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position.

Leases

The Company recognizes right of use assets and corresponding liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Each lease is classified as either finance or operating. This classification determines the presentation of corresponding expenses over the lifetime of the lease. The Company records long-term leases as liabilities at the present value of the minimum lease payments not yet paid. The Company’s incremental borrowing rate is used to determine the present value of the leases when the implicit rate is not readily determinable. Certain lease contracts contain non-lease components such as maintenance, utilities, fuel and other services. The Company recognizes both the lease and non-lease component for each right of use asset.

Short-term leases (that have an initial term less than 12 months or that are cancellable by the lessor and lessee without significant penalties) are expensed on a straight-line basis over the lease term.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk. Terms of convertible and other promissory notes are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities is required to be revalued at each reporting date, with corresponding changes in fair value recorded in the current period operating results. These derivative liabilities arose due to the issuance of variably priced convertible notes. For the periods ended March 31, 2023 and December 31, 2022, the Company had derivative liabilities of $772,611 and $1,008,868, respectively.

Beneficial Conversion Features

In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options” the Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.

Foreign Currency Translation

The functional currency and the reporting currency of the Company’s US operations is United States dollars, (“USD”). The functional currency of the Company’s Canadian operations in Canadian dollars (“CAD”), Management has adopted ASC 830 “Foreign Currency Matters” for transactions that occur in foreign currencies. Monetary assets denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Average monthly rates are used to translate revenues and expenses.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income for the respective periods.

Assets and liabilities of the Company’s operations are translated into the reporting currency, United States dollars, at the exchange rate in effect at the balance sheet dates. Revenue and expenses are translated at average rates in effect during the reporting periods. Equity transactions are recorded at the historical rate when the transaction occurred. The resulting translation adjustment is reflected as accumulated other comprehensive income, a separate component of stockholders' equity in the statement of stockholders' equity. These translation adjustments are reflected in accumulated other comprehensive income, a separate component of the Company's stockholders' equity.

Harmonized Sales Tax

The Harmonized Sales Tax (“HST”) is a combination of the Canadian Goods and Services Tax (“GST”) and Provincial Sales Tax (“PST”) that is applied to taxable goods and services. By fusing sales tax at the federal level with sales tax at the provincial level, the participating provinces harmonized both taxes into a single federal-provincial sales tax. HST is a consumption tax paid by the consumer at the point of sale (POS). The vendor or seller collects the tax proceeds from consumers by adding the HST rate to the cost of goods and services. They then remit the total collected tax to the government periodically.

The HST is in effect in five of the ten Canadian provinces: New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, and Prince Edward Island. The HST is collected by the Canada Revenue Agency (CRA), which remits the appropriate amounts to the participating provinces. The HST may differ across these five provinces, as each province will set its own PST rates within the HST. In provinces and territories which have not enacted the HST, the CRA collects only the 5% goods and services tax. The current rate in Ontario is 13%.

Stock-Based Compensation

The Company has adopted ASC Topic 718, (Compensation—Stock Compensation), which establishes a fair value method of accounting for stock-based compensation plans. In accordance with guidance now incorporated in ASC Topic 718, the cost of stock options and warrants issued to employees and non-employees is measured on the grant date based on the fair value. The fair value is determined using the Black-Scholes option-pricing model. The resulting amount is charged to expense on a straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The fair value of stock warrants was determined at the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option model requires management to make various estimates and assumptions, including expected term, expected volatility, risk-free rate, and dividend yield. The Company had no stock options outstanding at March 31, 2023.

Goodwill and Intangible Assets

Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of customer relationships and non-compete agreements. Their useful lives range from 10 to 15 years. The Company’s indefinite-lived intangible assets consist of trade names.

Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures, and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.

Determining the fair value of a reporting unit is judgmental and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test before scheduled annual impairment tests.

Long-Lived Assets

The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value.

Fair Values of Assets and Liabilities

The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded, and the reliability of the assumptions used to determine fair value.

	Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

	Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Financial Instruments

The estimated fair value for financial instruments was determined at discrete points in time based on relevant market information. These estimates involve uncertainties and could not be determined with exact precision. The fair value of the Company’s financial instruments, which include cash, prepaid expenses, accounts payable, and the related party loan, each approximate their carrying value due either to their short length to maturity or interest rates that approximate prevailing market rates.

Income Taxes

The Company accounts for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

Income (Loss) Per Share

Income (loss) per share is presented in accordance with Accounting Standards Update (“ASU”), Earning per Share (Topic 260) which requires the presentation of both basic and diluted earnings per share (“EPS”) on the income statements. Basic EPS would exclude any dilutive effects of options, warrants, and convertible securities but does include the restricted shares of common stock issued. Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted EPS calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations. The Company adopted ASC 842 on January 1, 2019. However, the adoption of the standard had no impact on the Company’s financial statements since all Company leases are month to month or short-term rental.

NOTE 2.

GOING CONCERN AND LIQUIDITY

As of March 31, 2023 and December 31, 2022, the Company had a cash overdraft $(34,050) and $2,317 in cash on hand, respectively, and no revenue-producing business or other sources of income. Additionally, as of March 31, 2023, the Company had negative working capital totaling $17,734,391 and an accumulated deficit of $96,107,912.

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Based on its current financial projections, the Company believes it does not have sufficient existing cash resources to fund its current limited operations. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern.

It is the Company’s current intention to raise debt and/or equity financing to fund ongoing operating expenses. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company. Any issuance of equity securities, if accomplished, could cause substantial dilution to existing stockholders. Any failure by the Company to successfully implement these plans would have a material adverse effect on its business, including the possible inability to continue operations.

NOTE 3.

INVESTMENT

As of March 31, 2023, and December 31, 2022, the balance of investments was $-0- and $78,760, respectively.

On October 6, 2020, the Company invested $50,000 CAD ($39,270 USD) in exchange for 83,333 Class A Common Shares at $0.60 CAD per share of Klonetics Inc.. The Company entered into a cooperation agreement with Klonetics Plant Science Inc., a Company that engages in the business of genetics research and development, tissue culture propagation, plantlet production, ready to flower production within the cannabis industry throughout the world. The parties considered it advantageous to pool their respective experience, expertise, know-how and capabilities in the area of land acquisition, financing, development, operations, and respective areas of industry focus. The parties wished to commence their intended long-term cooperation by pursuing projects in selected areas of focus initially before extending it to a larger scale merger between the parties, which may be discussed at a later date with terms to be determined and agreed to by the parties. CannaPharmaRx will invest up to a maximum percentage of Thirty Percent (30%) of the issued and outstanding shares of Klonetics.

On January 15, 2021, the Company invested an additional $50,000 CAD ($39,490 USD) in exchange for an additional 83,333 Class A Common Shares at $0.60 CAD per share of Klonetics Inc.

During the three months ended March 31, 2023, the Company determined that its investment in Klonetics had no value and wrote off its entire investment to zero. As a result the Company recorded a loss on investment of $78,760 on its Statements of Operations for the three months ended March 31, 2023.

NOTE 4.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable are recognized initially at the transaction price and subsequently measured at the undiscounted amount of cash or other consideration expected to be paid. Accrued expenses are recognized based on the expected amount required to settle the obligation or liability.

The following table sets forth the components of the Company’s accrued liabilities on March 31, 2023, and December 31, 2022.


	March 31, 2023		December 31, 2022

Accounts payable and accrued expenses	$	7,212,230	$	6,882,947
Accrued interest (a)		183,423		151,925
Accrued legal settlement (b)		190,000		190,000
Total accounts payable and accrued liabilities	$	7,585,653	$	7,224,872

(a)	Represents interest accrued on the outstanding convertible notes and other notes – (see Note 12, Notes Payables)

(b)

The Company had previously been a party to an action filed by Gary M. Cohen, a former officer and director of the Company in 2014. In March 2015, the Company entered into a Settlement Agreement with Mr. Cohen wherein the Company agreed to repurchase 2,250,000 shares of its Common Stock from Mr. Cohen in consideration for $350,000. Mr. Cohen passed away while there was a remaining balance of $190,000 remaining to be paid in accordance with the Settlement Agreement. The Company has taken the position that his death has discharged any obligation the Company might have to make the balance of the payments. The Company has not received any demand for payment or otherwise been involved in any attempt to collect this balance for a period of greater than two years prior to the date of this Report.

NOTE 5.

RELATED PARTY TRANSACTIONS

The following table sets forth the components of the Company’s related party liabilities on March 31, 2023 and December 31, 2022.

Schedule of related party liabilities
	March 31, 2023		December 31, 2022
Loan payable, related parties(a)	$	414,056	$	74,497
Total loan payable, related parties	$	414,056	$	74,497

(a)

The loan payable related parties is comprised of an interest-free loan $49,138 from the former Company's CEO and a $364,917 loan from a shareholder of the Company and principal of Koze Investments pursuant to the following : On May 25, 2023 the Company entered into a one year maturity from the date of each advance an unsecured Master Promissory Note agreement ("Master Note") with Koze Investments, LLC. ("Koze") under the terms of the Master Note, Koze agreed to advance up to $2,000,000 to the Company in funding to pay for certain documented Company expenses. The Note bears interest at 24% compounded monthly.

NOTE 6.

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

The following tables set forth the components of the Company’s, convertible debentures as of March 31, 2023, and December 31, 2022:


	March 31, 2023		December 31, 2022

Principal value of convertible notes	$	1,344,252	$	1,303,452
Note discount		–		(162,392	)
Total convertible notes, net current	$	1,344,252	$	1,141,060

During the three months ended March 31, 2023, and March 31, 2022, the Company received proceeds from convertible notes of $153,750 and $476,250, respectively.

March 31, 2023 Activity

During the three months ended March 31, 2023, the Company received proceeds from convertible notes of $153,750.

During the three months ended March 31, 2023 the Company recorded $34,185 in interest expense on its convertible notes and amortized $162,392 of note discount which was charged to interest expense. As of March 31, 2023, there was $183,423 in accrued interest on these notes, and $-0- in unamortized note discount related to these notes. As of the date of this Report, all convertible notes were past due their maturity date. Additionally, as a result of the late filing of this Report, and the loss of the Company’s active listing in the OTC market, the penalty provisions of all convertible notes outstanding became effective. The Company estimated that the maximum penalty provisions amounted to one times the face value of all convertible notes outstanding and recorded an accrued liability for penalties amounting to $1,303,452.

During the three months ended March 31, 2023, the Company issued 20,619,992 common shares upon the conversion of $112,950 in convertible notes and recorded a loss on conversion of $390,447.

March 31, 2022 Activity

During the three months ended March 31, 2022, the Company received proceeds from convertible notes of $476,250.

During the three months ended March 31, 2022, the Company recorded $22,787 in interest expense on its convertible notes and amortized $109,970.73 of note discount which was charged to interest expense. As of March 31, 2022, there was $65,131 in accrued interest on these notes, and $293,985 in unamortized note discount relating to these notes. As of the date of this Report, there were eight notes amounting to $698,017 that was past due its maturity date. The Company has not received any notice of default on these notes and continues to accrue interest on these notes past the maturity date.

During the three months ended March 31, 2022, the Company issued 28,186,741 common shares upon the conversion of $248,767 in convertible notes and recorded a loss on conversion of $246,994.

As of March 31, 2023 and December 31, 2023, the balances of derivative liabilities $772,611 and $1,008,868. As of December 31, 2023 were valued using a probability-weighted average Black-Scholes-Merton pricing model with the following assumptions:


	March 31, 2023
Exercise Price		$0.00375-$.00750
Stock Price		$0.009
Risk-free interest rate		4.73%
Expected volatility		213.80%
Expected life (in years)		1.0
Expected dividend yield		0%
Fair Value	$	772,611

The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility of its common stock. The expected life of the conversion feature of the notes was based on the remaining term of the notes. The expected dividend yield was based on the fact that the Company has not customarily paid dividends in the past and does not expect to pay dividends in the future.

NOTE 7.

NOTES PAYABLE

The following tables set forth the components of the Company’s, convertible debentures as of March 31, 2023, and December 31, 2022:

Schedule of notes payable
	March 31, 2023		December 31, 2022
Principal value of Promissory Notes	$	7,721,894	$	7,715,858
Promissory Note		7,721,894		7,715,858

Pursuant to the terms of the Securities Purchase Agreement with AMS, the Company issued a non-interest-bearing CAD $10,000,000 ($7,330,000 USD) promissory note secured only by the shares acquired in AMS. Principal payments under the Promissory Note are due quarterly commencing upon AMS receiving a license to cultivate and are computed based upon 50% of AMS' cash flow, defined as EBITDA less all capital expenditures, taxes incurred, non-recurring items, and other non-cash items for the relevant fiscal quarter, including the servicing of all senior debt payment obligations of the Company. The Promissory Note matures the earlier of two years from the date AMS receives a license to cultivate, or December 31, 2021. Since AMS had not received its cultivation license as of December 31, 2020, the Note Payable has a maturity date of December 31, 2021 and is past due.

The Company performed a valuation study as part of the AMS acquisition. The valuation study determined that the Promissory Note should be valued at $6,632,917 since it was non-interest bearing. As a result, the Company recorded a note discount of $697,083. The note discount will be amortized to interest expense over the three-year term of the Promissory Note. During the year ended December 31, 2021, the Company has recorded $186,610 in amortization expense related to this note discount.

On July 3, 2019, the Company entered into a 12% $1,000,000 Loan Agreement with Koze Investments LLC (“Koze”), payable in full on June 28, 2020. Under the terms of the 12% Note, Koze took a first security interest against the Company’s Hanover, Ontario cannabis facility in progress and required the Company to pay off its existing mortgage of approximately $650,000 CAD. Additionally, the Company agreed to pay a 3% origination fee, prepay the year of interest ($60,000) and to issue to Koze five-year warrants to purchase 1,001,000 shares of the Company’s Common Stock at an exercise price of $1.00 per share. After paying the origination fees, the prepayment and paying off the original mortgage, the Company used a portion of the remaining proceeds as payment against the SMI purchase price of CAD $1,000,000. During the period ended December 31, 2020, the Company recorded an additional amount of $890,570 relating to penalties for late payment. On July 9, 2021, the Company closed the sale of the Hanover property and used the proceeds from the sale to repay this note in full. The note was repaid for $1,600,000 which included the original principal of $1,000,000, accrued interest of $124,735 and penalties of $475,265. This mortgage has now been discharged.

On April 21, 2020, the Company received a loan from the Government of Canada under the Canada Emergency Business Account program (CEBA). This loan was in the amount of $40,000 CAD (USD $29,352). These funds are interest-free until December 31, 2022, at which time the remaining balance will convert to a 3-year term loan at an interest rate of 5% per annum. An additional amount of $20,000 CAD (USD $15,708) was received on December 29, 2020. If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 33% or $20,000 CAD.

During the year ended December 31, 2021, the Company entered into Note Agreements with secured investors amounting to $238,560. These notes are non-interest bearing and mature in 12 months. Repayment includes principal amount plus $50,000 CAD settlement cash fee plus 58,140 Common Shares at $0.43 per share plus 59,524 Common Shares at $0.42 per share. These notes are secured by a General Security Agreement over all present and after acquired property, assets, and undertakings. These notes are past due.

NOTE 8.

INCOME TAXES

As of December 31, 2022, the Company has approximately $94,700,000 of federal net operating loss carryforwards (“NOLS”) in the United States. The federal net operating loss carryforwards begin to expire in 2030. State net operating loss carryforwards begin to expire in 2034. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s net operating loss carryforwards could be subject to annual limitations against taxable income in future periods which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carryforward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation there could be a substantial reduction in the deferred tax asset with an offsetting reduction in the valuation allowance. As of March 31, 2023, the Company has no unrecognized income tax benefits.

The tax years from 2014 and forward remain open to examination by federal and state authorities due to net operating loss and credit carryforwards. The Company is currently not under examination by the Internal Revenue Service or any other taxing authorities. Since the company has never been profitable, the Company has established a full valuation allowance against the deferred tax asset associated with the NOLS.

NOTE 9.

COMMITMENTS AND CONTINGENCIES

Effective February 1, 2023, the Company entered into a lease agreement to lease one office at 520 -5^th Avenue SW, Calgary, Alberta, Canada, T2P 3R7. The lease may be terminated by either party on 30 days’ notice. The rent is $500 CAD per month. This space was provided by a company to which Mr. Orman, one of the Company’s directors, serves as a Director.

NOTE 10.

STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is authorized to issue up to 10,000,000 shares of one or more series of Preferred Stock, par value of $0.0001 per share. The Board of Directors may, without stockholder approval, determine the dividend rates, redemption prices, preferences on liquidation or dissolution, conversion rights, voting rights, and any other preferences.

Series A Preferred Stock

In April 2018, the Company issued 60,000 shares of its Series A Convertible Preferred Stock for $1.00 per share to certain investors who then became members of management and the board of directors. Each share of Series A Convertible Preferred Stock is convertible into 1,250 shares of Common Stock and vote on an as-converted basis. The rights and designations of these Preferred Shares include the following:

	·	entitles the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders:

	·	The holders of outstanding Series A Convertible Preferred Stock shall only be entitled to receive dividends upon declaration by the Board of Directors of a dividend payable on the Company’s Common Stock, whereupon the holders of the Series A Convertible Preferred Stock shall receive a dividend on the number of shares of Common Stock into which each share of Series A Convertible Preferred Stock is convertible;

	·	Each Series A Preferred Share is convertible into 1,250 shares of Common Stock;

	·	not redeemable.

The beneficial conversion (“BCF”) feature attributed to the purchase of Preferred Stock was deemed to have no value on the date of purchase because there was no public trading market for the Convertible Preferred Stock, and none is expected to develop in the future. Therefore, the BCF related to the Preferred Shares was considered to have no value on the date of issuance.

There were 84,416 and 84,416 shares of Series A Preferred Stock issued and outstanding as of March 31, 2023, and December 31, 2022, respectively.

Series B Preferred Stock / Common Stock

In February 2019, the Company commenced an offering of up to $3 million in principal amount of Units at a price of $1.00 per Unit, each Unit consisting of one share of Series “B” Convertible Preferred Stock, each Convertible Preferred Share convertible into one share of the Company’s Common Stock at the election of the holder and one Common Stock Purchase Warrant exercisable to purchase one share of Common Stock at an exercise price of $2.00 per share, which offering is to be offered only to “accredited investors,” as that term is defined in Rule 501 of Regulation D. This Offering was closed at the end of August 2019. As of December 31, 2020, the Company had accepted $475,000 in subscriptions in this offering.

There were 2,455,000 and 2,475,000 shares of Series B Convertible Preferred Stock issued and outstanding as of March 31, 2023, and December 31, 2022, respectively.

Common stock

The Company is authorized to issue 5,000,000,000 shares of Common Stock, par value $0.0001 per share. As of March 31, 2023, and December 31, 2022, there were 294,764,614 and 274,124,622 shares of Common Stock were issued and outstanding, respectively.

Stock Options

During the period ended March 31, 2023, and December 31, 2022, the Company did not record any stock-based compensation expense related to stock options, as there were none outstanding.

Stock Purchase Warrants

As of March 31, 2023 there were 1,497,778 warrants outstanding with an average strike price of $0.79 and a remaining life of 2.6 years. These warrants have no intrinsic value.

During the three months ended March 31, 2023 and 2022, the Company recorded $45,245 in stock based compensation related to prior warrants issued being amortized over a five year period.

The value of the stock purchase warrants for the periods ended March 31, 2023, and March 31, 2022, was determined using the following Black-Scholes methodology:

Schedule of assumptions used for valuation of warrants
Expected dividend yield (1)			0.00%
Risk-free interest rate range (2)			0.07%
Volatility range			135%
Expected life (in years)			5.00

_____________

(1)	The Company has no history or expectation of paying cash dividends on its Common Stock.
(2)	The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.

NOTE 11. RIGHT OF USE ASSET

The majority of our lease obligations are finance leases for the buildings from which we conduct our business. For any lease with an initial term in excess of 12 months, the related lease assets and liabilities are recognized on the Consolidated Balance Sheets as either operating or finance leases at the inception of an agreement where it is determined that a lease exists.

Finance lease assets represent the right to use an underlying asset for the lease term, and finance lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are recognized based on the present value of future payments over the lease term at commencement date. We use a collateralized incremental borrowing rate based on the information available at commencement date, including lease term, in determining the present value of future payments. We update the incremental borrowing rate in the event of a lease modification such as a renewal or option that adds time and payments to a lease. Our lease terms generally do not include options to extend or terminate the lease unless there is a reasonable certainty that the options will be exercised. Fixed payments may contain predetermined fixed rent escalations. We recognize the expense related to finance leases using the effective interest rate method from the commencement date to the end of the lease term.

Leases with an initial term of 12 months or less are not recorded on our Condensed Consolidated Balance Sheets. We recognize lease expense for these leases using the straight-line method over the lease term.

The weighted average remaining lease term is 19.0 years and the weighted average discount rate is 16.9%.

The Company’s right of use assets as of March 31, 2023 were as follows:

Schedule of right of use assets
	March 31, 2023
	Gross Carrying Amount		Accumulated Depreciation		Net Book Value
Right of Use Buildings	$	5,401,883	$	337,618	$	5,064,265

Supplementary information on the Company’s lease liabilities as of March 31, 2023 included the following:

Schedule of lease liabilities
		March 31, 2023
Interest	$	237,307
Amortization and depreciation		67,569
Finance lease related expenses	$	304,876
Finance lease related payments	$	192,152

Future lease payments under our non-cancellable finance leases as of March 31, 2023 were as follows:

Schedule of Future lease payments under our non-cancellable finance leases
2023	576,065
2024	806,693
2025	846,921
2026	889,269
2027	931,617
2028	978,026
Thereafter	18,189,939
Total Undiscounted Cashflows	23,218,529
Imputed Interest	(17,757,382	)
Lease Liability	5,643,148

NOTE 12.

SUBSEQUENT EVENTS

On April 18, 2023 the Company issued 6,097,561 shares to Diagonal Lending to retire $29,250 of convertible debt.

On May 25, 2023 the Company entered into a one year maturity from the date of each advance an unsecured Master Promissory Note agreement (“Master Note”) with Koze Investments, LLC. (“Koze”) under the terms of the Master Note, Koze agreed to advance up to $2,000,000 to the Company in funding to pay for certain documented Company expenses. The Note bears interest at 24% compounded monthly. As of September 13, 2023 Koze had advanced approximately $1,380,000 to the Company pursuant to the terms of the Master Note and charged approximately $103,000 in interest on those advances.

The first harvest at the Company’s Cremora facility took place on August 10^th, 2023, and resulted in over 70 kilograms (kg) of hand trimmed, saleable cannabis flower. That harvest is currently awaiting final results through a certified laboratory to produce the Certificate of Analysis to confirm results on THC, CBD and Terpenes. The second room is being harvested later this month with a forecasted yield of over 100 kg of flower. A third and fourth room have also been planted and are expected to be harvested on October 02^nd and 26^th respectively.

Preliminary discussion with export partners, would set conditional per gram pricing at approximately $3.30 CDN/gr. This pricing matrix would be based on achieving satisfactory test results associated to THC and CBD content of the dried flower. Expected revenues for both harvests, if sold in their entirety, would be forecasted at $660,000 CDN. A third and fourth harvests are now planted, with similarly forecasted revenues. There can be no assurances that our crops will be successfully harvested, or that we can sell the harvest; and if we do at the price/s we expect to receive.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 14, 2021 any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements. These risks and factors include, by way of example and without limitation:

our ability to successfully commercialize our products and services on a large enough scale to generate profitable operations;

our ability to maintain and develop relationships with customers and suppliers;

our ability to successfully integrate acquired businesses or new brands;

the impact of competitive products and pricing;

supply constraints or difficulties;

the retention and availability of key personnel;

general economic and business conditions;

substantial doubt about our ability to continue as a going concern;

our need to raise additional funds in the future;

our ability to successfully recruit and retain qualified personnel in order to continue our operations;

our ability to successfully implement our business plan;

our ability to successfully acquire, develop or commercialize new products and equipment;

intellectual-property claims brought by third parties; and

the impact of any industry regulation.

During the three-month period ending March 31, 2023 the Company had no revenues from operations. Loss from operations for the three months ended March 31, 2023 was $1,412,573 compared with a loss in the prior year of 2,071,982. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

As used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms “CannaPharmaRx,” “Company,” “we,” “us,” and “our” refer to CannaPharmaRx, Inc. and our wholly-owned subsidiaries. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

The following discussion should be read in conjunction with our financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward-looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

Overview and History

On May 9, 2014, we entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRX, Inc., a Colorado corporation (“Canna Colorado”), and David Cutler, a former President, Chief Executive Officer, Chief Financial Officer and director of our Company. Under the Share Purchase Agreement, Canna Colorado purchased 1,421,120 shares of our common stock from Mr. Cutler and an additional 9,000,000 restricted common shares directly from us.

On May 15, 2014, as amended and effective January 29, 2015, we entered into an Agreement and Plan of Merger (the “Merger”) pursuant to which Canna Colorado became a subsidiary of our Company. In October 2014, we changed our legal name to “CannaPharmaRx, Inc.”

Pursuant to the Merger, all of the shares of our Common Stock previously owned by Canna Colorado were canceled. As a result of the aforesaid transactions, we became an early-stage pharmaceutical company whose purpose was to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology then under development.

In April 2016, we ceased operations. Our then management resigned their respective positions with our Company, with the exception of Mr. Gary Herick, who remained as one of our officers and directors until March 2019.

Effective December 31, 2018, the Company and Hanover CPMD Acquisition Corp. (“CPMD Hanover”) a newly formed, wholly-owned subsidiary, entered into a Securities Purchase Agreement with Alternative Medical Solutions, Inc., an Ontario, Canada corporation (“AMS”), its shareholders, wherein the Company acquired all of the issued and outstanding securities of AMS. AMS is a corporation organized under the laws of the Province of Ontario, Canada. As a result of the completion of the acquisition of AMS on December 31, 2019, the Company no longer fits the definition of a “shell company,” as defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act. It filed the required disclosure on Form 8-K/A with the SEC on February 14, 2019, advising that it was no longer a shell company pursuant to the aforesaid Rule.

On January 6, 2021, the Company executed an Agreement of Purchase and Sale through its wholly owned subsidiary, Alternative Medical Solutions Inc for the sale of the lands and premises located at Hanover, Ontario, Canada. The price was $2,000,000 CAD and the closing of this transaction occurred on July 9, 2021. As a result, and anticipation of the closing, the Company recorded an impairment of goodwill and fixed assets relating to the property of $7,962,694 during the year ended December 31, 2020. This property is security for a $1,000,000 US note with Koze Investments, LLC by way of a first charge ranking. At closing, the note was retired with the proceeds from the sale by repayment of the principal of $1,000,000, accrued interest of $124,735, and penalties of $475,265. This note was discharged on July 13, 2021.

Effective February 25, 2019, the Company acquired 3,936,500 shares and 2,500,000 Warrants to purchase 2,500,000 shares of Common Stock of GN Ventures, Ltd, Alberta, Canada, f/k/a Great Northern Cannabis, Ltd. (“GN”), in exchange for an aggregate of 7,988,963 shares of its Common Stock, from a former shareholder of GN. While no assurances can be provided, the Company believes this is the initial step in its efforts to acquire all or a significant portion of the issued and outstanding stock of GN. In May 2020, the Company exchanged 5,507,400 of its shares for 3,671,597 shares of GN.

GN owns a 60,000 square foot cannabis cultivation and grow facility located on 38 acres in Stevensville, Ontario, Canada. Because the Company is a minority shareholder of GN and GN is a privately held company, the Company cannot confirm that the information it currently has on GN’s operations is complete or fully reliable. GN estimates annual total production capacity from the Stevensville facility of up to 12,500 kilograms of cannabis. GN believes the Stevensville facility to be complete, and GN’s subsidiary, 9869247 Canada Limited, received a license to cultivate from the Canadian Ministry of Health on July 5, 2019. As a result, in October 2019, GN commenced cultivation activities and began generating revenues during the first calendar quarter of 2020. The Company expects that it will obtain additional information on the business activities of GN as it has renewed discussions to acquire additional interests and is performing its due diligence procedures.

Effective June 11, 2019, the Company entered into a Securities Purchase Agreement with Sunniva, Inc, a British Columbia, Canada corporation (“Sunniva”) wherein the Company agreed to acquire all of the issued and outstanding securities of Sunniva’s wholly-owned subsidiaries Sunniva Medical Inc. (“SMI”) and 1167025 B.C. LTD (“1167025”) for CAD $16.0 million in cash and a note in the principal amount of CAD $4.0 million. These companies are the current owners of the Sunniva Canada Campus, which includes construction assets for a planned 759,000 square-foot greenhouse located on an approximately 114-acre property in Okanagan Falls, British Columbia.

On June 8, 2020, the Company received a notice of termination of this Purchase Agreement, as amended, from Sunniva. As a result, the Company incurred a charge of $1,881,126 due to the write-off of its deposit to Sunniva, banking fees and prepaid expenses associated with the failed acquisition of Sunniva. The Company is in discussions with Sunniva, as well as an investment banker who received deposits from the Company, about recovering all or a portion of its deposits, banking fees, and prepaid expenses. The accompanying financial statements as of December 31, 2022, do not reflect potential recovery amounts related to Sunniva and other parties, if any.

On January 6, 2022, the Company entered into a 20-year operating lease with Formosa Mountain Ltd., for a cannabis production facility in Cremona, Alberta, Canada. The facility is a 55,000 square foot plant, built in 2015. Production and sales from, this facility are anticipated in Q3 of 2023.

Production and sales from this facility are anticipated in Q3 of 2023. The expected date of the first harvest, under the new license, is on or about August 08^th, 2023 with the second harvest expectedsometime in September 2023 Both harvests are expected to yield around 100KG of saleable cannabis flower product.

Preliminary discussion with export partners, would set conditional pe gram pricing at approximately $3.30 CDN/gr. This pricing matrix would be based on achieving satisfactory test results associated to THC and CBD content of the dried flower. Expected revenues for both harvests, if sold in their entirety, would be forecasted at $660,000.00 CDN. A third and fourth harvest are planned in Q4 with similarly forecasted revenues.

Our principal place of business is located at 3600 888-3^rd Street SW, Calgary, Alberta, Canada, phone 949-652-6838. Our website address is www.cannapharmarx.com.

Because we have not generated any revenues during our prior two years, the following is our Plan of Operation.

PLAN OF OPERATION

See Note 1 above for a detailed discussion of our current business activities and plan of operation, the contents of which are incorporated herein as if set forth.

Going Concern

Substantial doubt exists as to our ability to continue as a going concern based on the fact that we do not have adequate working capital to finance our day-to-day operations. The Company did not have any revenues for the three months ended March 31, 2023 and 2022. The Company’s operating deficit of $1,412,573 as of March 31, 2023 indicates substantial uncertainty about the Company’s ability to continue as a going concern. Management’s plans include engaging in further research and development and raising additional capital in the short term to fund such activities through sales of its common stock. Management’s ability to implement its plans and continue as a going concern may be dependent upon raising additional capital. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to further scale down or perhaps even cease the operation of our business. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty.

Results of Operations

The Company does not currently sell or market any products and did not have any sales in the three months ended March 31, 2023 or 2022. The Company will commence actively marketing products after the products have been cleared or approved by Health Canada, but there can be no assurance, however, that we will be successful in obtaining Health Canada clearance or approval for our products.

Costs of Goods Sold

The Company did not have sales for the three months ended March 31, 2023 or 2022 and, accordingly, there were no cost of goods sold.

Gross Profit and Gross Margin

For the three months ended March 31, 2023 and 2022, the Company had no gross profit or gross margin.

Operating Expenses

Our operating expenses consist primarily of general and administrative expenses, which include salaries, stock-based compensation expense and legal and professional fees associated with the costs for services or employees in finance, accounting, sales, administrative activities and the formation and compliance of a public company.

Overall operating expenses in three months ended March 31 2023 was $720,277 compared to $715,558 for the three months ended March 31, 2022, essentially no change in the 2023 period from 2022. G&A expenses and payroll expenses due to activity at the Cremora facility increased approximately $158,000 in the 2023 period offset by a reduction of approximately $151,000 in professional fees.

Other income (expense)

Other expense was $692,296 for the three months ended March 31, 2023, compared to other expense of $1,356,424, a decrease of $664,128. The decrease is primarily attributable in 2023 due to the change in fair value of the derivative liability of $821,289 offset by an increase of $70,204 in the loss from the extinguishment of debt, and an increase in the loss on investments of $78,760.

Net Income (Loss)

As a result of the foregoing, the Company had a net loss of $1,412,573, and a net loss of $2,071,982 for the periods ended March 31, 2023, and March 31, 2022, respectively.

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2023, we had a cash overdraft of $34,050 as compared to cash on hand of $2,317 at December 31, 2022.

Cash flows from operating activities

The Company used $611,739 in operating activities for the first three months ended March 31, 2023 as compared to $375,184, during the prior year comparable quarter. The difference in cash used in operating activities is attributable to changes in operating assets and liabilities in 2023 compared to 2022.

Cash flows from investing activities

The Company used $893, during the first three months ended March 31, 2023 in investing activities as compared to using $16,578 during the three-month period ended March 31, 2022. The difference is attributable to a decrease in the purchase of furniture during the three months ended March 31, 2023 compared to 2022.

Cash flows from financing activities

During the three months ended March 31, 2023, $493,309 was provided from financing activities, including $153,750 from convertible loans and notes payable. During the prior year’s quarter, the Company received $476,250 and notes payable and $40,015 from the sale of common stock.

In general, based on historical losses, the Company will be required to continue raising operating capital through debt and equity.

Currently, we have no committed source for any funds to allow us to complete any of our proposed acquisitions or projects. No representation is made that any funds will be available when needed. In the event funds cannot be raised if and when needed, we may not be able to carry out our business plan. Our inability to obtain funding for our projects will have a negative impact on our anticipated results of operations.

Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the three-month period ended March 31, 2023.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures - Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of March 31, 2023 at the reasonable assurance level. We believe that our financial statements presented in this Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations - Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting - There were no changes in our internal control over financial reporting during the period ended March 31, 2023, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As part of our acquisition of AMS, we assumed an action filed against AMS by Ataraxia Canada, Inc., alleging breach of contract, specifically, breach of a nonbinding term sheet providing for Ataraxia to acquire controlling interest in AMS and they are seeking $15 million in damages. A Statement of Claim was prepared by Ataraxia Canada, Inc., as plaintiff, and circulated to Alternative Medical Solutions Inc., as defendant, on August 2, 2018, under the Ontario Superior Court of Justice (Court file no. CV-17-580157). The parties have engaged in discussions with respect to a potential settlement of this matter. Counsel has advised that it believes it is premature to speculate on any outcome of this litigation, including the likelihood of a settlement or any potential liability at this time.

Our agreement to acquire AMS contained a provision requiring us to diligently defend against the claims brought forth in, and assume full and complete control of, the Ataraxia litigation, provided that we shall not enter into any compromise or settlement in respect of the Ataraxia litigation without the prior written consent of the sellers, which consent is not to be unreasonably withheld, conditioned or delayed. The sellers are obligated to cooperate fully and make available to us all pertinent information and witnesses under their control, make such assignments and take such other steps as in the opinion of our counsel are reasonably necessary to enable us to defend against the claims brought forth in the Ataraxia litigation.

We are currently reviewing two separate situations with our legal counsel in order to ascertain whether we have claims against Steven Barber arising out of his default of the Consulting Agreement we entered into as part of the AMS acquisition more fully described in” Part I, Item 1,” Business, above and various claims against Gary Herick, a former officer and director. In January 2020, we received correspondence from counsel for Mr. Barber demanding payment on amounts purported to be due pursuant to his Consulting Agreement with us. We are currently reviewing whether Mr. Barber has performed pursuant to the terms of the Consulting Agreement.

No decision on whether to proceed on either of these situations has been reached as of the date of this Report.

On July 9, 2020, we filed a lawsuit in the United States District Court for the District of Colorado (1:20-cv-01999-RM-GPG) against Gary Herick, Arrowhead Consulting, LLC, Whitemoon Energy LLC., Jamie Huttrer a/k/a Jamie Huttrer-Herick, and ZeroRMW, LLC (collectively, the “Herick Parties”). The lawsuit alleges, among other things, the Herick Parties engaged in various legal violations including breach of fiduciary duty, common law fraud, conversion, usurpation of corporate opportunities, securities violations pursuant to Section 10b-5 of the Securities Exchange Act of 1934, and civil conspiracy. Mr. Herick was a former officer and director of the Company. On September 8, the Herick Parties filed a Motion to Dismiss the Sixth Claim for Relief (§ 10b-5 Federal Securities Law). On September 28, 2020, we filed a First Amended Complaint. On October 10, 2020, the Herick Parties filed a Motion to Dismiss the Fourth and Fifth Claims for Relief. On October 30, 2020, the Parties filed a Stipulated Motion for an Extension of Time, through and including November 16, 2020, for us to respond to the Herick Parties’ Motion to Dismiss the Fourth and Fifth Claims for Relief.

On July 9, 2020, we made a demand of Gary Herick, Arrowhead Consulting, LLC, Whitemoon Energy LLC., Jamie Huttrer a/k/a Jamie Huttrer-Herick, and ZeroRMW, LLC (collectively, the “Herick Parties”) for a return of with seeking the return of profits made between the period of August 2018, to January 2019. During this period, Gary Herick was the Chief Financial Officer and Director of the Company. Gary Herick was also the owner of approximately twenty-six percent (26%) of our common stock. Pursuant to the Securities Exchange Act of 1934, §16(b), 15 U.S.C.S. § 78p(b), an issuer may recover any profits realized by a beneficial owner from the sale of the issuer's equity securities within a six (6) month period. All unlawful profits must be returned to the Issuer on or before Tuesday, September 8, 2020.

On February 17, 2021, a Settlement Agreement and Release together with a Lock Up Agreement were signed by all parties to the lawsuit. As a result, the litigation has been discontinued.

On April 15, 2021, Bristol Capital Investors, LLC (BCI) filed a lawsuit in the Superior Court of the State of California, County of Los Angeles against CannaPharmaRx Inc. and Does 1 – 50, inclusive (Case No. 21^st CV1 3696). The lawsuit alleges that CannaPharmaRx Inc. (CPMD) breached the Amended and Restated Limited Liability Company Membership Purchase Agreement it had entered into with Bristol Capital Investors, LLC (BCI) to purchase BCI’s interest in Ramon Road Production Campus, LLC (RRPC), a single asset entity which owned an improved property, known as the Glass House, located in Cathedral City, California. BCI alleges causes of action for Fraud, Breach of Contract, Breach of the Implied Covenant of Good Faith and Fair Dealing, and Negligent Misrepresentation, and seeks compensatory and consequential damages in the amount of $10.5 millions dollars plus attorneys’ fees and costs. CPMD intends to vigorously defend against BCI’s lawsuit, going forward. The parties conducted a court-ordered mediation and the parties are engaging in on-going discussions.

We are not a party to any other legal proceeding or aware of any other threatened action as of the date of this Report.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended we issued 20,619,992 common shares pursuant to conversions of convertible debt to common stock. We also exchange 20,000 shares of Preferred B stock for 20,000 shares of common stock.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURE

Not Applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on September 22, 2023.

	CannaPharmaRx, Inc.


	By:	/s/ Dean Medwid
		Dean Medwid,
		Principal Executive Officer


	By:	/s/ John Cassels
		John Cassels, Principal Financial Officer and
		Principal Accounting Officer

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Dean Medwid, certify that:

I have reviewed this quarterly report on Form 10-Q of CannaPharmaRx, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 22, 2023

/s/ Dean Medwid

Dean Medwid, Chief Executive Officer

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, John Cassels, certify that:

I have reviewed this quarterly report on Form 10-Q of CannaPharmaRx, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 22, 2023

/s/ John Cassels

John Cassels, Chief Financial Officer

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report of CannaPharmaRx Inc. (the “Company”) on Form 10-Q for the three month period ended March 31, 2023, as filed with the Securities and Exchange Commission on September 22, 2023 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 22, 2023

/s/ Dean Medwid

Dean Medwid, Principal Executive Officer

Dated: September 22, 2023

/s/ John Cassels

John Cassels, Principal Financial Officer

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	Sep. 22, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	333-251016
Entity Registrant Name	CANNAPHARMARX, INC.
Entity Central Index Key	0001081938
Entity Tax Identification Number	27-4635140
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Suite 3600
Entity Address, Address Line Two	888 – 3rd Street SW
Entity Address, City or Town	Calgary
Entity Address, State or Province	AB
Entity Address, Country	CA
Entity Address, Postal Zip Code	T2P 5C5
City Area Code	949
Local Phone Number	652-6838
Title of 12(b) Security	Common Stock
Trading Symbol	CPMD
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		300,862,715

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 0	$ 2,317
HST Receivable	29,612	23,251
Prepaid expense	74,463	68,539
Other assets	0	5,906
Total current assets	104,075	100,014
Property, plant and equipment, net	102,848	107,780
Right of use building, net	5,064,265	5,127,622
Investments	0	78,760
Total Assets	5,271,189	5,414,176
Current liabilities
Accounts payable and accrued expenses	7,178,180	6,882,947
Cash overdraft	34,050	0
Accrued interest	183,423	151,925
Accrued legal settlement	190,000	190,000
Notes payable	7,721,894	7,715,858
Convertible notes -net of discount	1,344,252	1,141,060
Derivative liability	772,611	1,008,868
Loan payable - related parties	414,056	74,497
Total current liabilities	17,838,466	17,165,154
Liability for right of use building long-term	5,643,148	5,593,477
Total Liabilities	23,481,614	22,758,632
Commitments and contingencies
Stockholders' Deficit
Common stock, $0.0001 par value; 5,000,000,000 shares authorized, 294,764,614 and 274,124,622 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	29,476	27,412
Treasury stock, 133,200 and 133,200 shares as of March 31, 2023 and December 31, 2022, respectively	(13)	(13)
Additional paid in capital	75,093,838	74,523,642
Accumulated deficit	(96,107,912)	(94,695,339)
Accumulated other comprehensive income (loss)	234,770	240,427
Total Stockholders' (Deficit)	(18,210,425)	(17,344,455)
Total Liabilities and Stockholders' (Deficit)	5,271,189	5,414,176
Series A Preferred Stock [Member]
Stockholders' Deficit
Preferred stock value	84,416	84,416
Series B Preferred Stock [Member]
Stockholders' Deficit
Preferred stock value	$ 2,455,000	$ 2,475,000

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	5,000,000,000	5,000,000,000
Common stock, issued	294,764,614	274,124,622
Common stock, outstanding	294,764,614	274,124,622
Treasury stock, Shares	133,200	133,200
Series A Preferred Stock [Member]
Preferred shares, par value	$ 1.00	$ 1.00
Preferred shares, authorized	100,000	100,000
Preferred shares, issued	84,416	84,416
Preferred shares, outstanding	84,416	84,416
Series B Preferred Stock [Member]
Preferred shares, par value	$ 1.00	$ 1.00
Preferred shares, authorized	3,000,000	3,000,000
Preferred shares, issued	2,455,000	2,475,000
Preferred shares, outstanding	2,455,000	2,475,000

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating Expenses:
General and administrative	249,699	139,435
Amortization and depreciation	73,399	74,064
Stock based compensation	45,245	45,245
Rent	2,593	4,739
Professional fees	26,201	177,404
Payroll and consulting fees	323,140	274,671
Total operating expenses	720,277	715,558
Loss from operations	(720,277)	(715,558)
Other income (expense)
Interest (expense)	(459,345)	(451,148)
Gain or (loss) on the extinguishment of debt	(390,447)	(320,243)
Loss on investments	(78,760)	0
Change in the fair value of derivative liability	236,256	(585,033)
Other (expense) net	(692,296)	(1,356,424)
Loss before provision for income taxes	(1,412,573)	(2,071,982)
Provision (credit) for income tax	0	0
Net loss	(1,412,573)	(2,071,982)
Comprehensive loss:
Foreign currency translation adjustment	(5,656)	(120,750)
Comprehensive (loss)	(1,418,229)	(2,192,732)
Supplemental disclosure of non-cash investing and financing activities:
Common stock issued as financing expense on convertible notes	0	17,000
Common stock issued to convert convertible notes and accrued interest into equity	$ 507,015	$ 501,905

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Earnings Per Share, Basic	$ (0.00)	$ (0.01)
Earnings Per Share, Diluted	$ (0.00)	$ (0.01)
Weighted Average Number of Shares Outstanding, Basic	292,889,614	149,215,596
Weighted Average Number of Shares Outstanding, Diluted	292,889,614	149,215,596

STATEMENTS OF CONSOLIDATED CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows From Operating Activities:
Net (loss)	$ (1,412,573)	$ (2,071,982)
Adjustments to reconcile net income to net cash provided by (used in) operating activities
Stock-based compensation expense	45,245	45,245
Loss on investments	78,760	0
Beneficial conversion feature of convertible notes	0	227,386
Amortization of debt discount	162,392	100,971
Loss on the extinguishment of debt	390,447	320,243
Change in the fair value of derivatives	(236,256)	585,033
Depreciation	5,826	942
Changes in operating assets and liabilities
HST Receivable	(6,342)	(4,098)
Right of use asset	0	(5,727,811)
Prepaids	(5,924)	0
Other assets	5,906	0
Lease liabilities for right of use asset	0	5,850,761
Accrued interest	31,498	16,633
Accrued expense related party	0	47,387
Accounts payable and accrued expense	329,283	234,106
Net cash (used in) operating activities	(611,739)	(375,184)
Cash Flows From Investing Activities:
Purchase of fixed assets	(893)	(16,578)
Net cash (used in) investing activities	(893)	(16,578)
Cash Flows From Financing Activities:
Proceeds from convertible notes	153,750	0
Proceeds from notes payable	339,559	476,250
Proceeds from the sale of common stock in private placements	0	40,015
Net cash provided by financing activities	493,309	516,265
Effect of exchange rates on cash and cash equivalents	117,005	(72,594)
Net Increase (Decrease) In Cash	(2,317)	51,909
Cash At The Beginning Of The Period	2,317	27,767
Cash At The End Of The Period	0	79,676
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash investing and financing activities:
Common stock issued as a financing expense on convertible notes	0	17,000
Common stock issued to convert convertible notes and accrued interest into equity	$ 0	$ 501,905

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series B [Member]	Common Stock [Member]	Treasury Stock Common And Preferred [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 67,191	$ 475,000	$ 12,551	$ (13)	$ 73,055,579	$ (86,164,319)	$ (371,909)	$ (12,925,920)
Beginning balance, shares at Dec. 31, 2021	67,191	475,000	125,509,810	133,200
Net (loss)						(2,071,982)		(2,071,982)
Change in foreign currency translation							(120,750)	(120,750)
Conversion of Series A Preferred to common stock	$ (9,011)		$ 1,126		7,885
Conversion of Series A Preferred to common stock, shares	(9,011)		11,263,750
Conversion of convertible notes to common shares			$ 2,819		499,096			501,915
Conversion of convertible notes to common shares, shares			28,186,741
Sale of common stock in private placement			$ 250		39,765			40,015
Sale of common stock in private placement, shares			2,500,000
Issuance of Series B shares for deposit on acquisition
Issuance of common stock for services
Commitment shares issued with convertible note			$ 100		16,900			17,000
Commitment shares issued with convertible note, shares			1,000,000
Beneficial conversion feature of convertible notes					227,386			227,386
Stock based compensation related to warrant issuances					45,245			45,245
Ending balance, value at Mar. 31, 2022	$ 58,180	$ 475,000	$ 16,846	$ (13)	73,891,856	(88,236,301)	(492,658)	(14,287,090)
Ending balance, shares at Mar. 31, 2022	58,180	475,000	168,460,301	133,200
Beginning balance, value at Dec. 31, 2022	$ 84,416	$ 2,475,000	$ 27,412	$ (13)	74,523,642	(94,695,339)	240,427	(17,344,455)
Beginning balance, shares at Dec. 31, 2022	84,416	2,475,000	274,124,622	133,200
Net (loss)						(1,412,573)		(1,412,573)
Change in foreign currency translation							(5,656)	(5,656)
Conversion of Series B Preferred to common stock		$ (20,000)	$ 2		19,998
Conversion of Series B Preferred to common stock, shares		(20,000)	20,000
Conversion of convertible notes to common shares			$ 2,062		504,953			507,015
Conversion of convertible notes to common shares, shares			20,619,992
Stock based compensation related to warrant issuances					45,245			45,245
Ending balance, value at Mar. 31, 2023	$ 84,416	$ 2,455,000	$ 29,476	$ (13)	$ 75,093,838	$ (96,107,912)	$ 234,770	$ (18,210,425)
Ending balance, shares at Mar. 31, 2023	84,416	2,455,000	294,764,614	133,200

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1.

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

On May 15, 2014, as amended and effective January 29, 2015, we entered into an Agreement and Plan of Merger (the “Merger”) pursuant to which Canna Colorado became a subsidiary of our Company.

In October 2014, we changed our legal name to “CannaPharmaRx, Inc.”

Description of Current Business

Basis of Presentation

All figures are in U.S. dollars unless indicated otherwise.

Use of Estimates

Cash and Cash Equivalents

Comprehensive Gain or Loss

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position.

Leases

Derivative Financial Instruments

Beneficial Conversion Features

Foreign Currency Translation

Harmonized Sales Tax

Stock-Based Compensation

Goodwill and Intangible Assets

Long-Lived Assets

Fair Values of Assets and Liabilities

	Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

	Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Financial Instruments

Income Taxes

Income (Loss) Per Share

Recently Issued Accounting Pronouncements

GOING CONCERN AND LIQUIDITY

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN AND LIQUIDITY

NOTE 2.

GOING CONCERN AND LIQUIDITY

INVESTMENT

3 Months Ended

Mar. 31, 2023

Investments, All Other Investments [Abstract]

INVESTMENT

NOTE 3.

INVESTMENT

As of March 31, 2023, and December 31, 2022, the balance of investments was $-0- and $78,760, respectively.

On January 15, 2021, the Company invested an additional $50,000 CAD ($39,490 USD) in exchange for an additional 83,333 Class A Common Shares at $0.60 CAD per share of Klonetics Inc.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

3 Months Ended

Mar. 31, 2023

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 4.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

The following table sets forth the components of the Company’s accrued liabilities on March 31, 2023, and December 31, 2022.


	March 31, 2023		December 31, 2022

Accounts payable and accrued expenses	$	7,212,230	$	6,882,947
Accrued interest (a)		183,423		151,925
Accrued legal settlement (b)		190,000		190,000
Total accounts payable and accrued liabilities	$	7,585,653	$	7,224,872

(a)	Represents interest accrued on the outstanding convertible notes and other notes – (see Note 12, Notes Payables)

(b)

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2023

RELATED PARTY TRANSACTIONS

NOTE 5.

RELATED PARTY TRANSACTIONS

The following table sets forth the components of the Company’s related party liabilities on March 31, 2023 and December 31, 2022.

Schedule of related party liabilities
	March 31, 2023		December 31, 2022
Loan payable, related parties(a)	$	414,056	$	74,497
Total loan payable, related parties	$	414,056	$	74,497

(a)

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

NOTE 6.

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

The following tables set forth the components of the Company’s, convertible debentures as of March 31, 2023, and December 31, 2022:


	March 31, 2023		December 31, 2022

Principal value of convertible notes	$	1,344,252	$	1,303,452
Note discount		–		(162,392	)
Total convertible notes, net current	$	1,344,252	$	1,141,060

During the three months ended March 31, 2023, and March 31, 2022, the Company received proceeds from convertible notes of $153,750 and $476,250, respectively.

March 31, 2023 Activity

During the three months ended March 31, 2023, the Company received proceeds from convertible notes of $153,750.

During the three months ended March 31, 2023, the Company issued 20,619,992 common shares upon the conversion of $112,950 in convertible notes and recorded a loss on conversion of $390,447.

March 31, 2022 Activity

During the three months ended March 31, 2022, the Company received proceeds from convertible notes of $476,250.

During the three months ended March 31, 2022, the Company issued 28,186,741 common shares upon the conversion of $248,767 in convertible notes and recorded a loss on conversion of $246,994.


	March 31, 2023
Exercise Price		$0.00375-$.00750
Stock Price		$0.009
Risk-free interest rate		4.73%
Expected volatility		213.80%
Expected life (in years)		1.0
Expected dividend yield		0%
Fair Value	$	772,611

NOTES PAYABLE

3 Months Ended

Mar. 31, 2023

Notes Payable

NOTES PAYABLE

NOTE 7.

NOTES PAYABLE

The following tables set forth the components of the Company’s, convertible debentures as of March 31, 2023, and December 31, 2022:

Schedule of notes payable
	March 31, 2023		December 31, 2022
Principal value of Promissory Notes	$	7,721,894	$	7,715,858
Promissory Note		7,721,894		7,715,858

INCOME TAXES

3 Months Ended

Mar. 31, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 8.

INCOME TAXES

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 9.

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 10.

STOCKHOLDERS’ EQUITY

Preferred Stock

Series A Preferred Stock

	·	entitles the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders:

	·	The holders of outstanding Series A Convertible Preferred Stock shall only be entitled to receive dividends upon declaration by the Board of Directors of a dividend payable on the Company’s Common Stock, whereupon the holders of the Series A Convertible Preferred Stock shall receive a dividend on the number of shares of Common Stock into which each share of Series A Convertible Preferred Stock is convertible;

	·	Each Series A Preferred Share is convertible into 1,250 shares of Common Stock;

	·	not redeemable.

There were 84,416 and 84,416 shares of Series A Preferred Stock issued and outstanding as of March 31, 2023, and December 31, 2022, respectively.

Series B Preferred Stock / Common Stock

There were 2,455,000 and 2,475,000 shares of Series B Convertible Preferred Stock issued and outstanding as of March 31, 2023, and December 31, 2022, respectively.

Common stock

Stock Options

During the period ended March 31, 2023, and December 31, 2022, the Company did not record any stock-based compensation expense related to stock options, as there were none outstanding.

Stock Purchase Warrants

As of March 31, 2023 there were 1,497,778 warrants outstanding with an average strike price of $0.79 and a remaining life of 2.6 years. These warrants have no intrinsic value.

During the three months ended March 31, 2023 and 2022, the Company recorded $45,245 in stock based compensation related to prior warrants issued being amortized over a five year period.

The value of the stock purchase warrants for the periods ended March 31, 2023, and March 31, 2022, was determined using the following Black-Scholes methodology:

Schedule of assumptions used for valuation of warrants
Expected dividend yield (1)			0.00%
Risk-free interest rate range (2)			0.07%
Volatility range			135%
Expected life (in years)			5.00

_____________

(1)	The Company has no history or expectation of paying cash dividends on its Common Stock.
(2)	The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.

RIGHT OF USE ASSET

3 Months Ended

Mar. 31, 2023

Right Of Use Asset

RIGHT OF USE ASSET

NOTE 11. RIGHT OF USE ASSET

The weighted average remaining lease term is 19.0 years and the weighted average discount rate is 16.9%.

The Company’s right of use assets as of March 31, 2023 were as follows:

Schedule of right of use assets
	March 31, 2023
	Gross Carrying Amount		Accumulated Depreciation		Net Book Value
Right of Use Buildings	$	5,401,883	$	337,618	$	5,064,265

Supplementary information on the Company’s lease liabilities as of March 31, 2023 included the following:

Schedule of lease liabilities
		March 31, 2023
Interest	$	237,307
Amortization and depreciation		67,569
Finance lease related expenses	$	304,876
Finance lease related payments	$	192,152

Future lease payments under our non-cancellable finance leases as of March 31, 2023 were as follows:

Schedule of Future lease payments under our non-cancellable finance leases
2023	576,065
2024	806,693
2025	846,921
2026	889,269
2027	931,617
2028	978,026
Thereafter	18,189,939
Total Undiscounted Cashflows	23,218,529
Imputed Interest	(17,757,382	)
Lease Liability	5,643,148

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 12.

SUBSEQUENT EVENTS

On April 18, 2023 the Company issued 6,097,561 shares to Diagonal Lending to retire $29,250 of convertible debt.

Preliminary discussion with export partners, would set conditional per gram pricing at approximately $3.30 CDN/gr. This pricing matrix would be based on achieving satisfactory test results associated to THC and CBD content of the dried flower. Expected revenues for both harvests, if sold in their entirety, would be forecasted at $660,000 CDN. A third and fourth harvests are now planted, with similarly forecasted revenues. There can be no assurances that our crops will be successfully harvested, or that we can sell the harvest; and if we do at the price/s we expect to receive.

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

All figures are in U.S. dollars unless indicated otherwise.

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Comprehensive Gain or Loss

Comprehensive Gain or Loss

Reclassifications

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position.

Leases

Leases

Derivative Financial Instruments

Derivative Financial Instruments

Beneficial Conversion Features

Beneficial Conversion Features

Foreign Currency Translation

Foreign Currency Translation

Harmonized Sales Tax

Harmonized Sales Tax

Stock-Based Compensation

Stock-Based Compensation

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Long-Lived Assets

Long-Lived Assets

Fair Values of Assets and Liabilities

Fair Values of Assets and Liabilities

	Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

	Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Financial Instruments

Financial Instruments

Income Taxes

Income Taxes

Income (Loss) Per Share

Income (Loss) Per Share

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2023

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities


	March 31, 2023		December 31, 2022

Accounts payable and accrued expenses	$	7,212,230	$	6,882,947
Accrued interest (a)		183,423		151,925
Accrued legal settlement (b)		190,000		190,000
Total accounts payable and accrued liabilities	$	7,585,653	$	7,224,872

(a)	Represents interest accrued on the outstanding convertible notes and other notes – (see Note 12, Notes Payables)

(b)

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of related party liabilities

Schedule of related party liabilities
	March 31, 2023		December 31, 2022
Loan payable, related parties(a)	$	414,056	$	74,497
Total loan payable, related parties	$	414,056	$	74,497

(a)

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Schedule of components of convertible debentures


	March 31, 2023		December 31, 2022

Principal value of convertible notes	$	1,344,252	$	1,303,452
Note discount		–		(162,392	)
Total convertible notes, net current	$	1,344,252	$	1,141,060

Schedule of assumptions used for derivatives


	March 31, 2023
Exercise Price		$0.00375-$.00750
Stock Price		$0.009
Risk-free interest rate		4.73%
Expected volatility		213.80%
Expected life (in years)		1.0
Expected dividend yield		0%
Fair Value	$	772,611

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2023

Notes Payable

Schedule of notes payable

Schedule of notes payable
	March 31, 2023		December 31, 2022
Principal value of Promissory Notes	$	7,721,894	$	7,715,858
Promissory Note		7,721,894		7,715,858

STOCKHOLDERS’ EQUITY (Tables)

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

Schedule of assumptions used for valuation of warrants

Schedule of assumptions used for valuation of warrants
Expected dividend yield (1)			0.00%
Risk-free interest rate range (2)			0.07%
Volatility range			135%
Expected life (in years)			5.00

RIGHT OF USE ASSET (Tables)

3 Months Ended

Mar. 31, 2023

Right Of Use Asset

Schedule of right of use assets

Schedule of right of use assets
	March 31, 2023
	Gross Carrying Amount		Accumulated Depreciation		Net Book Value
Right of Use Buildings	$	5,401,883	$	337,618	$	5,064,265

Schedule of lease liabilities

Schedule of lease liabilities
		March 31, 2023
Interest	$	237,307
Amortization and depreciation		67,569
Finance lease related expenses	$	304,876
Finance lease related payments	$	192,152

Schedule of Future lease payments under our non-cancellable finance leases

Schedule of Future lease payments under our non-cancellable finance leases
2023	576,065
2024	806,693
2025	846,921
2026	889,269
2027	931,617
2028	978,026
Thereafter	18,189,939
Total Undiscounted Cashflows	23,218,529
Imputed Interest	(17,757,382	)
Lease Liability	5,643,148

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Cash overdraft	$ 34,050	$ 0
Cash and cash equivalents		2,317
Derivative liability	$ 772,611	$ 1,008,868
Minimum [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	10 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Intangible assets useful life	15 years

GOING CONCERN AND LIQUIDITY (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash overdraft	$ 34,050	$ 0
Cash and cash equivalents		2,317
Working Capital	17,734,391
Accumulated deficit	$ 96,107,912	$ 94,695,339

INVESTMENT (Details Narrative) - USD ($)			3 Months Ended
INVESTMENT (Details Narrative) - USD ($)	Jan. 15, 2021	Oct. 06, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Investments			$ 0		$ 78,760
Gain loss on investments			$ 78,760	$ 0
Canada, Dollars \| Class A Common Stock [Member] \| Klonetics Plant [Member]
Payment for investment	$ 50,000	$ 50,000
Stock received for investment	83,333	83,333

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 7,212,230	$ 6,882,947
Accrued interest (a)	183,423	151,925
Accrued legal settlement (b)	190,000	190,000
Total accounts payable and accrued liabilities	$ 7,585,653	$ 7,224,872

RELATED PARTY TRANSACTIONS (Details) - USD ($)

Mar. 31, 2023

Dec. 31, 2022

Total loan payable, related parties

$ 414,056

$ 74,497

Loans Payable [Member]

Total loan payable, related parties

^[1]

$ 414,056

$ 74,497

[1]

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Principal value of convertible notes	$ 1,344,252	$ 1,303,452
Note discount	0	(162,392)
Total convertible notes, net current	$ 1,344,252	$ 1,141,060

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Details 1) - Derivative Liabilities [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Offsetting Assets [Line Items]
Derivative liability fair value	$ 772,611
Measurement Input, Exercise Price [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	$0.00375-$.00750
Measurement Input, Share Price [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	$0.009
Measurement Input, Risk Free Interest Rate [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	4.73%
Measurement Input, Price Volatility [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	213.80%
Measurement Input, Expected Term [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	1.0
Measurement Input, Expected Dividend Rate [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	0%

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Proceeds from convertible notes	$ 153,750	$ 476,250
Accrued interest	183,423		$ 151,925
Change in the fair value of derivatives	236,256	(585,033)
Derivative liability	772,611		$ 1,008,868
Convertible Notes [Member]
Debt Instrument [Line Items]
Proceeds from convertible notes	153,750
Interest expense, debt	34,185	22,787
Amortization of note discount	162,392	109,970
Accrued interest	183,423	65,131
Unamortized note discount	0	$ 293,985
Accrued liability for penalties	$ 1,303,452
Debt converted, shares issued	20,619,992	28,186,741
Debt converted, amount converted	$ 112,950	$ 248,767
Change in the fair value of derivatives	$ 390,447	246,994
Note in default		$ 698,017

NOTES PAYABLE (Details) - Convertible Debentures [Member] - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal value of Promissory Notes	$ 7,721,894	$ 7,715,858
Promissory Note	$ 7,721,894	$ 7,715,858

NOTES PAYABLE (Details Narrative) - USD ($)				3 Months Ended	12 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 29, 2020	Apr. 21, 2020	Jul. 03, 2019	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2020
Secured Notes Payable [Member]
Debt face amount				$ 1,000,000
Debt maturity date				Dec. 31, 2021
Interest expenses					$ 186,610
Koze Investments [Member]
Debt face amount			$ 1,000,000
Debt maturity date			Jun. 28, 2020
Interest expenses			$ 60,000
Repayment of notes payable			$ 650,000
Penalties accrued						$ 890,570
Note Agreements [Member]
Promissory note carrying amount					$ 238,560
Canada, Dollars \| Secured Notes Payable [Member]
Debt face amount				$ 10,000,000
Canada, Dollars \| Canada Emergency Business Account [Member]
Proceeds from loans	$ 20,000	$ 40,000
United States of America, Dollars \| Secured Notes Payable [Member]
Debt face amount				7,330,000
Promissory note carrying amount				6,632,917
Original issue discount				$ 697,083
United States of America, Dollars \| Canada Emergency Business Account [Member]
Proceeds from loans	$ 15,708	$ 29,352
Loan term		3 years

INCOME TAXES (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carryforwards		$ 94,700,000
Unrecognized income tax benefits	$ 0

STOCKHOLDERS' EQUITY (Details) - Stock Purchase Warrants [Member]	3 Months Ended
	Mar. 31, 2023
Measurement Input, Expected Dividend Rate [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	0.00%
Measurement Input, Risk Free Interest Rate [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	0.07%
Measurement Input, Price Volatility [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	135%
Measurement Input, Expected Term [Member]
Offsetting Assets [Line Items]
Derivatives, Determination of Fair Value	5.00

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	3 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Apr. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common Stock, Shares Authorized	5,000,000,000		5,000,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Common stock, issued	294,764,614		274,124,622
Common stock, outstanding	294,764,614		274,124,622
Stock based compensation	$ 45,245	$ 45,245
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding	1,497,778
Weighted Average Exercise Price	$ 0.79
Average Remaining Contractual Life (Years)	2 years 7 months 6 days
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, issued	84,416		84,416	60,000
Preferred shares, par value	$ 1.00		$ 1.00	$ 1.00
Preferred Stock, Shares Outstanding	84,416		84,416
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, issued	2,455,000		2,475,000
Preferred shares, par value	$ 1.00		$ 1.00
Preferred Stock, Shares Outstanding	2,455,000		2,475,000
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, issued	10,000,000
Preferred shares, par value	$ 0.0001

RIGHT OF USE ASSET (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Right Of Use Asset
Right of use buildings, gross carrying amount	$ 5,401,883
Right of use buildings, accumulated depreciation	337,618
Right of use buildings, net book value	$ 5,064,265	$ 5,127,622

RIGHT OF USE ASSET (Details 1)	3 Months Ended
RIGHT OF USE ASSET (Details 1)	Mar. 31, 2023 USD ($)
Right Of Use Asset
Interest	$ 237,307
Amortization and depreciation	67,569
Finance lease related expenses	304,876
Finance lease related payments	$ 192,152

RIGHT OF USE ASSET (Details 2)	Mar. 31, 2023 USD ($)
Right Of Use Asset
2023	$ 576,065
2024	806,693
2025	846,921
2026	889,269
2027	931,617
2028	978,026
Thereafter	18,189,939
Total Undiscounted Cashflows	23,218,529
Imputed Interest	(17,757,382)
Lease Liability	$ 5,643,148